Abemaciclib 50 MG; 150mg 1-0-1 per os
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer Female
Conditions
Breast Cancer Female
Trial Timeline
Sep 2, 2020 → Jul 1, 2029
NCT ID
NCT04565054About Abemaciclib 50 MG; 150mg 1-0-1 per os
Abemaciclib 50 MG; 150mg 1-0-1 per os is a phase 3 stage product being developed by Eli Lilly for Breast Cancer Female. The current trial status is active. This product is registered under clinical trial identifier NCT04565054. Target conditions include Breast Cancer Female.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04565054 | Phase 3 | Active |
Competing Products
20 competing products in Breast Cancer Female